Ferring is committed to building a portfolio of novel, innovative drugs to address the indications of high unmet medical need for patients in our therapeutic areas of interest.
We would welcome proposals focused on the following:
The impact of the gut microbiota on GI related diseases. The immunological basis of gastrointestinal (GI) disorders such as celiac disease. Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease and the role of inflammatory processes in metabolic liver diseases including non-alcoholic steatohepatitis (NASH).
Identification of targets with utility in the prevention and/or treatment of preterm labor or preeclampsia. New modalities for the treatment of endometriosis or menopausal symptoms. Improving fertility by targeting the molecular basis of embryo implantation, oocyte, embryo quality, FSH non-responders, anovulatory disorders, ovarian aging, polycystic ovarian syndrome or male factor infertility.
Novel approaches to treat prostate related disorders, such as secondary hypogonadism and benign prostatic hyperplasia, with specific interest in the causes of progression to castration resistant and hormone sensitive prostate cancer. Identification of targets and biomarkers for use in the treatment of disorders such as painful bladder syndrome/interstitial cystitis, refractory overactive bladder, and/or non-muscle invasive bladder cancer.
View complete Ferring Innovation Grants Program Summary